Ray KK - Search Results

1

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.

Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Ray KK, et al. Arch Intern Med. 2010 Jun 28;170(12):1024-31. doi: 10.1001/archinternmed.2010.182. Arch Intern Med. 2010. PMID: 20585067 Review.

2

Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS.

Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, McCabe CH, Braunwald E, Gibson CM; PROVE IT-TIMI 22 Investigators. Ray KK, et al. Eur Heart J. 2006 Oct;27(19):2310-6. doi: 10.1093/eurheartj/ehl180. Epub 2006 Aug 3. Eur Heart J. 2006. PMID: 16887854 Clinical Trial.

3

Intensive statin therapy for treating acute coronary syndromes.

Ray KK, Cannon CP. Ray KK, et al. Expert Opin Investig Drugs. 2006 Oct;15(10):1151-9. doi: 10.1517/13543784.15.10.1151. Expert Opin Investig Drugs. 2006. PMID: 16989592 Review.

4

Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?

Ray KK, Cannon CP, Ganz P. Ray KK, et al. Am J Cardiol. 2006 Dec 4;98(11A):18P-25P. doi: 10.1016/j.amjcard.2006.09.016. Epub 2006 Sep 29. Am J Cardiol. 2006. PMID: 17126675 Review.

5

Recent trials of lipid lowering.

Ray KK, Cannon CP, Braunwald E. Ray KK, et al. Int J Clin Pract. 2007 Jul;61(7):1145-59. doi: 10.1111/j.1742-1241.2007.01425.x. Int J Clin Pract. 2007. PMID: 17577297 Free article. Review.

6

Aggressive statin therapy for acute coronary syndromes.

Vun Liew T, Ray KK. Vun Liew T, et al. Among authors: ray kk. Curr Cardiol Rep. 2007 Jul;9(4):298-302. doi: 10.1007/BF02938378. Curr Cardiol Rep. 2007. PMID: 17601396 Review.

7

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.

Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Ray KK, et al. Lancet. 2009 May 23;373(9677):1765-72. doi: 10.1016/S0140-6736(09)60697-8. Lancet. 2009. PMID: 19465231

8

Diabetes: Which risk engines should be used to assess patients with diabetes?

Ray KK, Sattar N. Ray KK, et al. Nat Rev Endocrinol. 2009 Jun;5(6):302-3. doi: 10.1038/nrendo.2009.100. Nat Rev Endocrinol. 2009. PMID: 19465897 No abstract available.

9

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Emerging Risk Factors Collaboration; Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Emerging Risk Factors Collaboration, et al. JAMA. 2009 Jul 22;302(4):412-23. doi: 10.1001/jama.2009.1063. JAMA. 2009. PMID: 19622820 Free PMC article. Review.

10

Major lipids, apolipoproteins, and risk of vascular disease.

Emerging Risk Factors Collaboration; Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Emerging Risk Factors Collaboration, et al. Among authors: ray kk. JAMA. 2009 Nov 11;302(18):1993-2000. doi: 10.1001/jama.2009.1619. JAMA. 2009. PMID: 19903920 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

393 results

Search Page